retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished ADA 2026: Retatrutide Revolution
Description
Others apply it specifically to sub-milligram doses that require compounded formulations
The Strength Training Protocol I Use With GLP-1 Clients Training on an appetite suppressant requires a different approach than a standard fat loss program
Maintaining a simple log takes seconds per entry and prevents the most common long-term protocol errors
However, outside of a labour-intensive clinical trial setting, long-term weight loss is notoriously difficult to achieve [3, 4]
The reasons for this issue vary, from poor education on how to take the medication to forgetfulness
